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ABSTRACT
Tumor vaccine after high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) aims
at directing immune recovery toward tumor responses after optimizing minimal residual disease. We have
characterized T-cell recovery and tumor response after a regimen devised as a platform for such immuno-
therapy. One hundred patients with high-risk or metastatic breast cancer received 3 to 7 cycles of paclitaxel and
cyclophosphamide (overall response rate, 78%) and then HDC with melphalan and etoposide. Seventy-one
patients received HDC and ASCT (no mortality at 100 days). At 24 months after transplantation, progression-
free and overall survival probabilities for patients with stage IIIA, IIIB, and IV disease were 82%, 81%, and 42%
and 100%, 94%, and 68%, respectively. The median progression-free and overall survivals from entry on study
for stage IV patients were 15.3 and 38.1 months, respectively. CD3, CD8, and CD4 cells were severely
depleted after ASCT. Although total CD8 T-cell numbers approached the normal range by 3 months, most
of these cells were CD28. Naive CD45RACD4 T cells approached the normal range only 18 months after
ASCT and only in younger patients. The described observations provide the basis for devising a strategy for
cancer vaccine administration after ASCT. Incorporating immune reconstitution enhancement after ASCT
may be advantageous.
© 2005 American Society for Blood and Marrow Transplantation
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ﬁNTRODUCTION
The role of high-dose chemotherapy (HDC) and
utologous stem cell transplantation (ASCT) in the d
72reatment of solid tumors such as high-risk and met-
static breast cancer remains controversial and unde-
ned. ASCT allows for an increase in chemotherapy
ose well beyond bone marrow tolerance in an at-
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Establishing a Platform for Immunotherapy
Bempt to maximally capitalize on the dose-response
urve of certain antineoplastic drugs (particularly al-
ylating agents) and, hence, maximally reduce the
umor burden [1,2]. In treating breast cancer in the
djuvant setting, the Dutch national study [3] showed
15% disease-free survival advantage (P  .05) at 5
ears with HDC over conventional chemotherapy in
atients with high-risk nonmetastatic disease (10
nvolved axillary lymph nodes), although other phase
II trials do not show survival advantages for HDC
ompared with conventional-dose therapy [4-9]. In
etastatic breast cancer, randomized trials so far have
ot shown an overall survival advantage to HDC [10-
2]. Irrespective of the ﬁnal analysis of all the studies
n progress, any beneﬁt observed is likely to be mod-
st, and this highlights the need to develop novel
pproaches.
Immune-based therapy using cancer vaccines after
DC and ASCT is a new strategy aimed at directing
-cell recovery after transplantation to target tumor-
peciﬁc antigens (TAA). The application of strategies
hat combine chemotherapy and immunotherapy re-
uires consideration of tumor biology, the patient’s
mmune system, the interaction between the 2, and
he effect of chemotherapy on each of these. In the
ase of cellular immunotherapy, it has been argued
hat chemotherapy may create “T-cell space” and en-
ance the effect of such immunotherapy [13].
When vaccines are used as cancer immunother-
py, achieving a state of minimal residual disease may
e critical. A reduction in tumor bulk may reduce the
mmune suppression induced by the tumor itself, in-
luding the state of tumor tolerance associated with
he inefﬁciency of the patient’s antitumor immunity.
n addition, post-ASCT immune strategies may re-
uire a prolonged time for effectiveness. This is illus-
rated in chronic myeloid leukemia with the progres-
ive conversion from cytogenetic to molecular
emission observed over a period of months after
llogeneic transplantation [14]. HDC regimens in
reast cancer have shown trends toward improve-
ents in time to progression in metastatic disease and
isease-free survival in the adjuvant setting (compared
ith standard-dose regimens), consistent with a
reater reduction in tumor bulk [7,10,11,15,16]. Of
he 14 randomized trials of HDC and ASCT, the 6
rials (totaling 2702 patients) in which both groups
eceived identical treatments except for a single course
f HDC in the experimental group demonstrated
ewer relapses in the high-dose group than in the
ontrol group [3,7,17-20]. Thus, HDC, through a
ore complete induction of minimal residual disease,
ay provide a platform for subsequent vaccine-based
herapies. However, chemotherapy has profound ef-
ects on the patient’s immune system, including de-
letion of lymphocyte subpopulations [21,22], and in-
act lymphocyte subpopulations are required to n
B & M Tenerate an immune response to a vaccine antigen,
nlike autologous cellular immunotherapy strategies.
fter HDC, the total number of CD3 T cells ini-
ially recovers relatively rapidly, but the number of
D4 T cells may never fully recover. B-cell num-
ers, but not function, return to normal range by 3 to
months after ASCT.
After bone marrow transplantation, the nature of
he T-cell lymphoid reconstitution is dependent on
he presence or absence of a functional thymus [22-
4]. In adults, immune reconstitution occurs predom-
nantly through peripheral expansion [24], in which T
ells expand after stimulation at the time of antigen
ncounter. Therefore, the reconstituted T-cell reper-
oire not only is biased toward the various antigens
andomly encountered during the period of immune
econstitution, but can also be deliberately skewed
oward antigens of choice by repeated exposure [25] in
he form of the administration of cancer vaccines [26].
Chemotherapy regimens developed for use with
ancer vaccines should (1) have acceptable toxicity, (2)
ffectively treat the disease to allow an interval for
accines to mediate an effect, and (3) be associated
ith immune competence sufﬁcient to support a re-
ponse to administered tumor antigen. In this study
or high-risk and metastatic breast cancer patients, we
ssessed a chemotherapy regimen for its ability to
chieve an optimal state of minimal residual disease
ith acceptable toxicity. With the aim of thoroughly
nderstanding post-HDC immune reconstitution for
otential application in posttransplantation vaccine
herapy, lymphocyte subsets and other indicators of
mmune reconstitution (T-cell receptor rearrange-
ent excision circle [TREC] analysis and repertoire
iversity analysis by spectratyping) were evaluated
oth before and, sequentially, after ASCT.
The primary aims of this study were to establish
he toxicity and efﬁcacy of this regimen combination
n high-risk and metastatic breast cancer and to study
atterns of immune reconstitution after ASCT in a
rospective, single-institution study as a prelude for
eveloping a combination chemotherapy/immuno-
herapy regimen.
ETHODS
atient Population
Between September 1996 and March 2004, 102
atients with high-risk (stage III) or metastatic (stage
V) breast cancer were enrolled on this study (Na-
ional Cancer Institute 96-C-0104). All patients had a
istologically conﬁrmed diagnosis reviewed by the
aboratory of Pathology of the National Cancer In-
titute. Stage III patients were eligible if they had
eceived either no prior therapy or prior adjuvant or
eoadjuvant chemotherapy (without disease refracto-
473
r
i
t
t
r
a
i
c
e
c
a
b
d
s
w
T
r
c
a
p
1
9
d
f
s
c
c
d
m
p
r
s
c
c
r
b
i
A
T
o
w
c
D
C

s
l
c
C
i
p
e
d
m
m
s
c
T
N
M
I
I
E
H
N
P
A
N
N
T
N
M
C
C
N
S
E
H
N
P
P
P
T
R
P
C. Sportès et al.
4iness or progression). Stage IV patients were eligible
f their disease was newly diagnosed or at ﬁrst relapse;
hey may have received adjuvant chemotherapy more
han 12 months previously and/or 1 chemotherapy
egimen as initial therapy for metastatic disease, with
t least a partial response (PR) at enrollment. An
nterval of18 months was later required between the
ompletion of adjuvant therapy and diagnosis of dis-
ase recurrence. On-study staging studies included
omputed tomographic (CT) scan of the head, chest,
bdomen, and pelvis and bone scan. Patients with
rain metastases were excluded. This study was con-
ucted with the approval of the National Cancer In-
titute Institutional Review Board. All patients gave
ritten informed consent.
reatment
Induction Therapy. This regimen was based on the
esults of a study that showed response rates of this
ombination of up to 73% in previously treated met-
static breast cancer [27].
Paclitaxel/cyclophosphamide (TC) consisted of
aclitaxel 53.3 mg/m2/d, continuous infusion on days
to 3 (total dose, 160 mg/m2), and cyclophosphamide
00 mg/m2/d, intravenously on days 1, 2, and 3 (total
ose of 2700 mg/m2). Granulocyte colony-stimulating
actor 5 g/kg/d was given from day 5 until the ab-
olute neutrophil count (ANC) returned to 1000
ells per microliter. During the peripheral blood stem
ell (PBSC) mobilization cycle (cycle 2), the 5g/kg
ose was given twice daily. All patients received a
inimum of 3 cycles before proceeding to the next
hase of treatment. Patients with measurable disease
eceived additional cycles to maximum tumor re-
ponse (maximum of 9 cycles). For the doxorubicin/
able 1. Patient Characteristics: Stage III Patients
Variable Data
umber of stage III patients 36
edian age, y (range) 47.8 (24-69)
IIA (%) 14 (39)
IIB (%) 22 (61)
Inflammatory 17
Noninflammatory 5
strogen or progesterone receptor positive (%) 20 (56)
er-2
Negative/1 12 (33)
2 6 (17)
3 14 (39)
Unknown 4 (11)
o prior therapy 29 (81)
rior therapy (anthracycline based) 7 (19)
djuvant 22 (61)
odal status
0–3 4 (18)
4–10 7 (31)
>10 11 (50)
eoadjuvant 14 (39)yclophosphamide regimen, patients who had not re- C
74eived an anthracycline before entry on the study
eceived, after TC chemotherapy, 4 cycles of doxoru-
icin 60 mg/m2 and cyclophosphamide 600 mg/m2
ntravenously every 3 weeks. Thus, before HDC and
SCT, all patients received a minimum of 3 cycles of
C and an anthracycline-containing regimen either
n study or as previous adjuvant therapy for patients
ith relapsed disease.
Apheresis for PBSCs. PBSCs were collected and
ryopreserved by using standard procedures of the
epartment of Transfusion Medicine of the Clinical
enter. After TC cycle 2, once the CD34 count was
20/L, the patient began daily 15- to 25-L aphere-
is. A white blood cell count (WBC) 5000/L al-
owed proceeding to apheresis regardless of the CD34
ount. A minimum total collection of 2.0  106
D34 cells per kilogram was required for proceed-
ng with HDC.
HDC and ASCT. High-dose melphalan and eto-
oside (ME) has been shown to have response rates
xceeding 50% in metastatic breast cancer [28]. On
ays 6, 5, and 4, melphalan 53.3 mg/m2 (160
g/m2 total dose) and etoposide 600 mg/m2 (1800
g/m2 total dose) were given. Granulocyte colony-
timulating factor 5 g/kg/d, started on day 0, was
ontinued until the ANC was 1000/L.
Locoregional Therapy and Additional Therapy. Lo-
able 2. Patient Characteristics: Stage IV Patients
Variable Data
umber of stage IV patients 66
edian age, y (range) 43.5 (27-69)
linical and pathologic diagnosis (%) 62 (94)
linical diagnosis alone (%) 4 (6)
umber of sites of disease (%)
1 36 (55)
2 26 (39)
>3 4 (6)
ites (%)
Lung 27 (41)
Bone 25 (38)
Nodal 18 (27)
Liver 13 (20)
Skin/soft tissue 8 (12)
strogen or progesterone receptor positive (%) 36 (55)
er-2 (%)
negative/1 25 (38)
2 0
3 20 (30)
Unknown 21 (32)
o prior therapy (%) 17 (26)
rior induction chemotherapy only 13 (19)
rior adjuvant therapy 36 (55)
Prior anthracycline 29
Prior taxane 7
Prior CMF 9
rior adjuvant and induction chemotherapy 8 (11.5)
ime since prior adjuvant chemotherapy (mo) 22.7
ange (mo) 0.5-86.6
rior hormonal therapy (%) 17 (27.9)MF indicates cyclophosphamide, methotrexate, 5 ﬂuorouracil.
c
m
w
t
4
T
r
a
a
a
m
H
c
c
e
c
f
u
w
c
i
e
t
R
a
P
p
m
d

a
e
m
F
a
n
b
i
n
0
a
e
a
-
(
p
c
c
C
d
w
c
t
t
F
l
T
P
M
Establishing a Platform for Immunotherapy
Boregional therapy (surgery and radiation) and hor-
onal therapy (tamoxifen 20 mg daily for 5 years)
ere assessed individually. Patients with bone metas-
ases received pamidronate 90 mg intravenously every
weeks.
oxicity and Disease Response Evaluation
All patients underwent clinical and radiologic
estaging (CT scan of chest, abdomen, and pelvis
nd bone scan) after the ﬁrst 3 TC cycles and then
fter every 2 cycles. Restaging studies were repeated
t the completion of TC (including brain CT or
agnetic resonance imaging immediately before
DC). After transplantation, patients underwent
linical and radiologic restaging at 6 weeks and then
linical evaluation every 3 months with imaging
very 6 months for 2 years. They then underwent
linical and imaging re-evaluation every 6 months
or 1 year and then yearly clinical re-evaluation
ntil they were off protocol. No imaging studies
ere performed after 3 years unless clinically indi-
ated. Immunologic re-evaluations were performed
mmediately before HDC and after the ASCT, ev-
ry 3 to 6 months for 2 years, and then yearly
hereafter.
esponse Criteria
Complete response (CR) indicates complete dis-
ppearance of all measurable and evaluable disease;
R indicates a decrease 50% in the sum of the
roducts of the longest perpendicular parameters of
able 3. Toxicities of Paclitaxel/Cyclophosphamide and Melphalan/Etop
Variable Grade 1
aclitaxel/cyclophosphamide
Anemia 31 (8%)
Neutropenia 0
Thrombocytopenia 92 (24%)
Nausea 75 (20%)
Vomiting 65 (17%)
Mucositis 68 (18%)
Diarrhea 107 (28%)
Peripheral neuropathy 23 (6%)
Hypersensitivity 11 (3%)
Pain 34 (9%)
Fatigue 20 (5%)
Hematuria 3 (1%)
Thromboembolism 0
Total bilirubin 0
elphalan/etoposide
Nausea 5 (9%)
Vomiting 21 (36%)
Diarrhea 14 (24%)
Esophagitis 1 (2%)
Mucositis 2 (3%)
Bilirubin, total 1 (2%)
Aspartate aminotransferase 35 (60%)
Alanine aminotransferase 28 (48%)easurable lesions with an improvement in evaluable t
B & M Tisease; and progressive disease (PD) indicates a
25% increase in any measurable disease, the appear-
nce of new disease, or an increase in evaluable dis-
ase. Stable disease was deﬁned as disease that did not
eet criteria for CR, PR, or PD.
low Cytometric Analyses
Peripheral blood, collected in heparin, was stained
t 4°C with a panel of antibodies, lysed with ammo-
ium chloride-ethylenediaminetetraacetic acid lysing
uffer, washed with ﬂuorescence-activated cell-sort-
ng buffer (Hanks buffered salt solution without phe-
ol red [Gibco, Grand Island, NY] supplemented with
.1% sodium azide and 0.2% bovine serum albumin),
nd analyzed on a FACSort (BDIS, San Jose, CA)
quipped with a 480-nm argon laser. The following
ntibodies were used: anti-CD3, -CD4, -CD8,
CD14, -CD28, -CD45, -CD45RA, and -CD62L
BD Biosciences, San Diego, CA). Total leukocyte
opulations were identiﬁed by using CD45-ﬂuores-
ein isothiocyanate and CD14-phycoerythrin. CD8
ells were deﬁned as CD3CD8 and CD4 cells as
D3CD4. Naive CD4 T cells were further
eﬁned as CD4CD45RACD62L; memory cells
ere calculated by subtraction. The total number of
ells per microliter expressing a particular pheno-
ype was calculated by multiplying the WBC (de-
ermined by a Coulter Counter; Coulter, Hialeah,
L) by the frequency of that population in the
ymphocyte acquisition gate and the fraction of the
bsolute Number and Percentage of Cycles with the Toxicity)
Grade 2 Grade 3 Grade 4
198 (52%) 139 (37%) 13 (3%)
0 3 (0.8%) 378 (99%)
115 (30%) 106 (28%) 68 (18%)
40 (10%) 7 (2%) 0
19 (5%) 3 (0.8%) 1 (0.3%)
35 (9%) 15 (4%) 0
63 (17%) 17 (4%) 2 (0.5%)
2 (0.5%) 2 (0.5%) 0
21 (6%) 0 (0%) 0
40 (10%) 8 (2%) 0
17 (4%) 5 (1%) 0
0 1 (0.3%) 1 (0.3%)
0 7 (2%) 2 (0.5%)
23 (6%) 17 (4.5%) 3 (0.8%)
22 (38%) 25 (43%) 0
24 (41%) 7 (12%) 0
17 (29%) 13 (22%) 2 (3%)
10 (17%) 17 (29%) 4 (7%)
10 (17%) 31 (53%) 6 (10%)
16 (28%) 6 (10%) 0
16 (28%) 2 (3%) 0
12 (21%) 2 (3%) 0oside (Aotal WBC included in the acquisition gate.
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4tatistical Methods
The total cells per microliter expressing a partic-
lar lymphoid subset phenotype were compared be-
ween patients younger and older than 45 years (ap-
roximately the population median age) at 1, 2, and 3
ears, as available, by using a Wilcoxon rank-sum test.
ithin each age category, changes in the mean num-
er of total cells per microliter between 2 consecutive
ears were obtained by subtracting the earlier year
alue from the later year value. These changes were
ested for whether they differed signiﬁcantly from 0
y using the Wilcoxon signed rank test. Because of the
ultiple comparisons performed, a P value of .01
as required for statistical signiﬁcance.
Time to progression was calculated in 2 ways: ﬁrst,
or all patients, from the on-study date until the date
f progression or last follow-up, and second, from the
BSC date until the date of progression or last follow-
p. Patients off study without disease progression had
his end point censored at that date. Survival time was
alculated from the on-study date until the date of
Figure 1. Kaplan-Meier survival curves froeath or last follow-up. Actuarial analyses were per- d
76ormed with the Kaplan-Meier method [29]. Data
ere stratiﬁed by stage (IIIA, IIIB, and IV), and a
og-rank test was performed to test for homogeneity
mong strata [30]. All P values are 2 tailed and are
resented without adjustment for multiple compari-
ons.
ESULTS
Patient characteristics for patients with stage III
nd IV disease are summarized in Tables 1 and 2,
espectively. Two patients withdrew voluntarily from
he study: 1 never received any chemotherapy, and the
ther received 1 cycle and refused follow-up and fur-
her treatment.
C Toxicity
Of the 102 enrolled patients, 100 patients received
total of 394 cycles of TC and were evaluable for TC
oxicity (Table 3). Twenty patients required dose re-
n-study date and (B) transplantation date.m (A) ouction, and 5 required more than 1 modiﬁcation. Dose
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Establishing a Platform for Immunotherapy
Beductions occurred for gastrointestinal toxicity (43%),
rolonged neutropenia (32%), or thrombocytopenia
16%) and grade 3 peripheral neuropathy (8%). Overall,
9% of TC cycles were complicated by febrile neutro-
enia requiring hospitalization, and an infectious source
as documented in 109 cycles (28.6%).
esponse to Induction Chemotherapy
Fifty-nine patients had measurable disease and
ere evaluable for response to TC induction. There
ere 14 (23.7%) CRs, 32 (54.2%) PRs (response rate,
8%), 5 (8.4%) instances of stable disease, and 8
13.6%) PDs. Overall, 15 patients had disease pro-
ression or an insufﬁcient response that precluded
ransplantation: 9 patients (1 stage III and 8 stage IV)
ad disease progression while receiving TC and 6
atients while receiving doxorubicin/cyclophospha-
ide after TC. An additional 12 patients did not
roceed to transplantation: 3 patients with insufﬁcient
BSC collection, 1 patient with prolonged pancyto-
enia despite 2 TC dose modiﬁcations, and 8 patients
Figure 1ith voluntary withdrawal from the study. d
B & M TDC and ASCT
At the time of this analysis, 71 patients—29 (85%)
tage III and 42 (64%) stage IV patients—have re-
eived HDC and ASCT. ME was mainly associated
ith the expected hematologic toxicity, but it was
ssociated with signiﬁcant gastrointestinal toxicity as
ell (Table 3). More than 80% of patients experi-
nced grade2 mucositis, and 33 (46%) of 79 patients
ad grade 2 esophagitis. Four patients required ad-
ission to the intensive care unit: 3 patients for neu-
ropenic fever with hemodynamic instability and 1
atient with pulmonary hemorrhage requiring me-
hanical ventilation (fully recovered). A median of
.6  106 (range, 2.4-39.5  106) CD34 cells were
einfused. The median number of days to ANC 500
nd platelet count 50 000/L were 9 days (range,
-13 days) and 13 days (range, 10-25 days), respec-
ively. The median length of hospitalization for ASCT
as 18 days (range, 13-63 days).
Forty patients were not evaluable for tumor response
o ME, including 28 of the 29 patients with stage III
tinued). (Conisease who had no evidence of disease at the time of
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4DC. At the 6-week posttransplantation tumor re-eval-
ation, 2 patients with stage IV and 1 with stage IIIB
nﬂammatory disease had disease progression.
osttransplantation-Related Complications
There was no 100-day mortality. One patient de-
eloped fatal progressive multifocal leukoencephalop-
thy 6 months after transplantation, and 2 patients
eveloped a myelodysplastic syndrome.
urvival Analysis
For the 100 evaluable patients, the median poten-
ial follow-up time on study is 67.6 months. Progres-
ion-free and overall survival percentage estimates
rom entry on study and from ASCT are detailed in
able 4, and Figure 1 shows the corresponding
aplan-Meier curves. For stage III patients, the me-
ian progression-free survivals have not been reached,
nd for stage IV patients, they are 15.3 months from
he on-study date and 13.2 months from the trans-
lantation date.
ymphocyte Reconstitution after ASCT
Shown in Figure 2 are the absolute values for total
D3, CD4, naive CD4 (deﬁned as CD4,
D45RA, CD62L phenotype), and CD8 T cells
efore treatment, at the time of transplantation, at 6
eeks, 3 months, and then every 3 months until 24
onths after transplantation. All populations were de-
leted to well below the lower limit of normal at the
ime of HDC. After ASCT, the median CD3 and
D8 T-cell counts showed an initial increase into
he normal range at 6 weeks then declined toward
aseline numbers at 3 months. The median CD3 and
D8 T-cell numbers reached the normal range 15
nd 12 months after transplantation, respectively, and
emained within the normal range thereafter, al-
hough a large number of the CD8 cells were
D28 (Table 5). In contrast, CD4 T cells were
able 4. Survival Percentages
Years
Stage from On-Study
Date
Stage from PBSC
Date
IIIA IIIB IV IIIA IIIB IV
% Progression-Free Survival
1 86 90 68 91 88 54
2 78 78 37 82 81 42
3 70 78 30 65 81 36
4 53 78 30 65 81 36
% Overall Survival
1 93 95 89 100 94 83
2 93 90 67 100 94 68
3 93 90 53 83 94 54
4 77 90 40 83 86 45everely depleted by the HDC and remained signiﬁ- a
78antly below normal for the ﬁrst 2 years after ASCT.
n particular, the number of naive CD4 T cells did
ot approach the normal range until the end of the
econd year after ASCT, and this occurred only in the
ounger patients; no patient older than 50 years of age
t the time of transplantation has recovered a normal
umber of naive CD4 T cells. Table 5 shows im-
une reconstitution data evaluated at 3 annual points,
omparing the mean results by age group. Immune
econstitution differed signiﬁcantly between the 2
roups in several subsets. Data in Table 6 also dem-
nstrate via mean changes that recovery of the various
opulations continued during the second year after
SCT in the younger patients but did so to a much
esser extent in the older patients. There was no fur-
her recovery beyond 24 months in either age group.
o signiﬁcant associations were found between recov-
ry of each lymphocyte subset and the amount of
hemotherapy received on protocol, the total amount
f chemotherapy received, stage of disease, or survival
data not shown).
ISCUSSION
An HDC regimen that can result in a prolongation
f time to tumor progression or recurrence may in-
rease the window in which an immune-based strategy
an have its effect. The therapeutic strategy presented
ere was investigated as a treatment platform for sub-
equent immune therapeutic interventions such as the
dministration of cancer vaccines. It includes an HDC
egimen to maximally reduce tumor burden and op-
imize the progression-free interval, with the speciﬁc
oal of incorporating a subsequent antitumor vaccine
trategy.
In this study, we demonstrated that the combina-
ion of induction chemotherapy with TC followed by
DC with ME and ASCT is a highly effective treat-
ent strategy for high-risk and metastatic breast can-
er. The TC induction chemotherapy did result in
ncreased, but well-manageable, hematologic toxicity
ut showed excellent antitumor activity in both stage
II and IV patients, with an overall response rate of
8%. The ME combination is safe and effective as a
retransplantation conditioning regimen for breast
ancer, with no 100-day mortality. Time-to-engraft-
ent parameters were similar to those of other con-
itioning regimens; acute toxicity was manageable
ith supportive measures, and other posttransplanta-
ion complications were infrequent.
Our results, at a median potential follow-up time
f 67.6 months, compare favorably, most notably in
etastatic disease, with other transplant series, includ-
ng data from the Autologous Blood and Marrow
ransplant Registry, which estimated, for stage III
nd IV patients, a progression-free survival probability
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Bt 24 months of approximately 67% and 23%, respec-
ively, and an estimated 24-month overall survival of
pproximately 80% and 42%, respectively [31]. In
ontrast, at 24 months, our study shows, for patients
ith stage IIIA, IIIB, and IV disease who underwent
ransplantation, probabilities of progression-free sur-
ival of 82%, 81%, and 42%, respectively, and of
verall survival of 100%, 94%, and 68%, respectively.
n this study, the probability of patients with stage IV
isease being progression free 1 year after ASCT was
4%, thereby providing a prolonged relapse-free win-
ow of opportunity for the incorporation of additional
mmune-based therapeutic strategies coinciding with
he ongoing immune reconstitution.
The multifaceted monitoring of immune effector
ubset reconstitution after transplantation, including
henotyping (presented here), T-cell receptor (TCR)
pectratyping, and TREC analysis [32], provides a
etailed understanding of the effects of HDC and
SCT on selected immune cell populations and has
een instrumental in the concept development of
osttransplantation immune-based strategies. A criti-
al consideration in combining chemotherapy and im-
une-based treatments is the recovery of the various
ymphocyte subpopulations, because intact CD4 and
D8 subpopulations are required for functional ef-
ector responses and, hence, for the potential success
f vaccine-based immune therapy.
igure 2. Reconstitution of T-cell subsets after transplantation. Abso
n study (PRE TRT), after all chemotherapy, and at various time, CD3; B, CD4; C, CD445RA; D, CD8.
B & M TPosttransplantation immune reconstitution has
een shown to occur through 2 primary pathways.
he thymic pathway, which predominates in children,
nvolves the development of T cells from pluripotent
ematopoietic stem cells that home to the thymus and
ndergo a process of expansion, differentiation, and
election. The resultant T cells, which bear a naive
henotype, display a diverse TCR repertoire and are
oised to recognize an array of foreign antigens. The
econd major pathway for T-cell regeneration, which
redominates in adults, is thymus independent [23]. It
onsists of the peripheral expansion of existing T cells
n which the increase in T-cell number is due to the
itotic division of mature lymphocytes driven in part
y exposure to their speciﬁc antigen. This results in a
oorly diversiﬁed T-cell repertoire, limited mostly to
cells that encounter their speciﬁc antigen during the
eriod of immune reconstitution. Furthermore, this
rocess is unable to restore T-cell numbers to pre-
reatment levels [25].
This study characterizes profound effects of
DC on the patient’s immune system, including
epletion of total CD3, CD4, and CD8 T-
ymphocyte subpopulations in this high-risk and
etastatic breast cancer population. It conﬁrms and
xtends to the setting of HDC and ASCT the re-
ults of previous studies, showing, in adults with
reast cancer, a slow increase in CD4 populations
mbers of cells per microliter are shown of peripheral blood at entry
ASCT. Light areas represent normal ranges, and horizontal barslute nu
s after
ndicate the median; each open circle represents a value for 1 patient. APB SCT indicates autologous peripheral blood stem cell transplantation.479
Table 5. Lymphocyte Subset Recovery at 12, 24, and 36 Months as a Function of Age at Entry on Study
Variable
Months after Transplantation
CD3 (NI: 650-2108) CD4 (NI: 362-1275) CD4CD45RA (NI: 90-300) CD8 (NI: 344-911) CD8CD28/Total CD8
12 24 36 12 24 36 12 24 36 12 24 36 12 24 36
Age <45 y 648.7 1040.3 1011.4 291.1 530.3 542.4 91.7 209.7 176.4 348.4 465.8 448.1 65% 75% —
Age >45 y 873.5 935.5 1095 297.6 312.3 451.6 44.3 65.7 88.6 584.0 606.7 615.2 42% 54% —
P value .75 .36 .84 .18 .0055 .27 .0024 .0007 .019 .14 .93 .44 .0038 .042 —
Data are mean count (per microliter).
NI indicates normal.
Table 6. Kinetics of Subset Recovery at 12 versus 24 Months and 24 versus 36 Months as a Function of Age at Entry on Study
Variable
Months after Transplantation
CD3 CD4 CD4CD45RA CD8 CD8CD28/Total CD8
12 versus 24 24 versus 36 12 versus 24 24 versus 36 12 versus 24 24 versus 36 12 versus 24 24 versus 36 12 versus 24 24 versus 36
Age <45 y (P value) 339 (.0040) 36.7 (.84) 212 (.0017) 56.5 (.44) 112 (.0010) 24.7 (.44) 99.2 (.079) 17.3 (.44) 10% (.011) —
Age >45 y (P value) 262.3 (.014) 33.1 (.20) 105.8 (.0020) 97.9 (.078) 37.6 (.0098) 14.6 (.38) 144.5 (.15) 137.4 (.25) 0 (.76) —
Data are differences in mean count (per microliter).
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Establishing a Platform for Immunotherapy
Bfter dose-intensive chemotherapy. During the ﬁrst
ear after cytotoxic chemotherapy, peripheral ex-
ansion of memory CD4 T cells (CD45RARO)
redominated, and this resulted in persistent TCR
epertoire deﬁcits, as demonstrated by TCR spec-
ratyping. The naive CD4 cells (CD45RORA)
ontributed little to CD4 recovery during this
ime, with only a very gradual increase in the second
ear after chemotherapy [33]. Similarly, after HDC
nd ASCT, CD4 T cells remained signiﬁcantly
elow the normal range for the ﬁrst 2 years, and the
aive CD45RA subpopulation did not approach
he normal range until 2 years after ASCT. CD8
ells approached the normal range by 12 months
nd remained within the normal range subse-
uently. The return of a naive CD4 cell popula-
ion determined by ﬂow cytometry correlates with
ther methods of evaluation of thymic function,
uch as thymic size, circulating TREC numbers,
nd normalized spectratype pattern of TCR rear-
angements [32]. The increase in naive CD4 cells
CD45RORA) correlates with an increase in the
umber of circulating TRECs indicative of the thy-
ic output of T cells having recently functionally
earranged their TCR.
Similarly, spectratyping patterns for most V
ene families return to the diverse, normally dis-
ributed pattern seen before treatment, and this
iversity of TCR rearrangements of new naive T
ells is the molecular basis for T-cell repertoire
ntigenic diversity. It is now also apparent through
he data of this study that, to regenerate normal
D4 T-cell numbers, a new pool of naive cells
ust be generated that will in time reconstitute a
iverse population of mature memory T cells. In the
atients older than 45 years in this study, the insuf-
cient reconstitution of a CD4-naive T-cell pool 2
ears after ASCT correlates with persistent low
otal CD4 T-cell numbers, whereas the younger
atients who regenerate an adequate number of
aive CD4 cells do reach normal T-cell numbers.
herefore, the re-emergence of naive T-cells does
ccur after HDC and ASCT but is delayed (18-24
onths) and age dependent. The identiﬁcation of
his late thymic recovery in adults provides an added
pportunity for a delayed immunization strategy
fter ASCT when repair of the naive T-cell reper-
oire occurs. It is possible that exposure to the TAA
n the context of late vaccination may stimulate the
mergence, from the naive T-cell pool, of T cells
ith new, more effective antitumor speciﬁcities.
he hypothesis that new T-cell immunity to TAA
an be acquired through the thymic pathway, late
fter intensive therapy, can be tested functionally in
he subset of patients in whom the prolonged dis-
ase-free period after ASCT allows time for the a
B & M Tpontaneous re-emergence of a naive T-cell popu-
ation.
Although total CD8 T-cell numbers usually re-
urn to baseline earlier after chemotherapy, subset
nalysis in this study has shown that, in the ﬁrst year,
he predominant CD8 T-cell subpopulation lacks
he CD28 coreceptor. These cells, which normally
epresent a small subset of CD8 cells, are typically
oorly responsive to stimulation, and this may have a
ritical effect on the generation of a functional im-
une response after transplantation. The recovery of
D8CD28 cells generally does not occur until 1
ear after the completion of therapy [34].
Although the peripheral expansion of T cells
esults in limited diversity of the regenerated T-cell
epertoire, it offers a unique opportunity to pur-
osefully shape the expanding repertoire by the
dministration of antigen in the form of cancer
accines in vivo during the early, thymic-indepen-
ent period of immune reconstitution. This has
een modeled with conventional antigens [25]. Fur-
hermore, murine studies have also shown that vac-
ination with irradiated, granulocyte-macrophage
olony-stimulating factor–producing autologous tu-
or cells in the posttransplantation period results in
onger tumor-free survival than the same vaccina-
ion in the nontransplantation setting [26]. Immu-
ization during the period of immune reconstitu-
ion resulted in sustained ampliﬁcation of this
ntitumor response, and this was closely associated
ith freedom from relapse. These results suggest
hat skewing of the T-cell repertoire against TAA
y using vaccines after transplantation holds prom-
se as a therapeutic strategy.
Finally, it may be possible to hasten the recovery
f some of these lymphocyte subpopulations. In a
eparate study (D. Fowler, personal communica-
ion, 2002), we optimized T-cell recovery by pro-
iding, after transplantation, autologous lympho-
ytes collected at a time when chemotherapy-
nduced immune damage had not yet occurred,
efore the start of treatment. Immune reconstitu-
ion was found to be signiﬁcantly improved in pa-
ients who received lymphocyte reinfusion and low-
ose interleukin 2 compared with the group of
atients who did not: at 9 months after chemother-
py, recipients of T cells and interleukin 2 had
igher CD4 (458/L) and CD4CD45RA (100/
L) counts than patients who received no interven-
ion (CD4, 290/L; CD4CD45RA, 45/L; P 
04 and .01, respectively). The strategy of posttrans-
lantation reinfusion of T cells collected before
hemotherapy may prove to be a critical adjunct to
ttempts at posttransplantation immunotherapy by
roviding an intact pool of memory T cells. More-
ver, the knowledge that immune reconstitution
fter intensive chemotherapy will have to rely, ini-
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4ially at least, primarily on memory T-cell reconsti-
ution emphasizes the need to maximize that path-
ay by providing up-front, by antitumor
mmunization before chemotherapy, an opportunity
o elicit a primary immune response and develop a
adre of tumor antigen–speciﬁc memory T cells.
eripheral lymphocytes containing these sensitized
cells may be cryopreserved before the initiation
f any chemotherapy and reinfused after all im-
une-depleting therapies have been delivered and
efore antitumor reimmunizations.
In conclusion, this study provides an analysis of
he reconstitution of various subsets of immune
ffectors after ASCT. This information is important
or the design of posttransplantation immune-based
herapies. It also reports a highly effective chemo-
herapy strategy. HDC with ASCT may ﬁnd its
ost important role as a platform for subsequent
mmune-based therapies by providing a state of
inimal residual disease and an optimized time of
isease-free survival sufﬁcient for immunotherapy
o be effective. These data support 3 strategies
ased on the unique circumstances present during
mmune reconstitution after T-cell depletion by
SCT. First, the period of profound CD8 T-cell
xpansion immediately after ASCT, which has been
hown in animal data to be antigen driven and,
herefore, subject to manipulation, offers an oppor-
unity for deliberate, TAA-targeted, antigen-driven
lonal expansion of T cells [13]. Second, there is a
oncomitant period of poor CD4 expansion,
hich, in preliminary results, can be augmented by
nfusion of T cells collected before chemotherapy.
hird, the emergence of a new T-cell repertoire
uring thymic recovery late after ASCT offers an
pportunity for late tumor vaccination. Therefore,
epeated vaccinations along with reinfusions of pre-
reatment TAA-sensitized T cells during the clini-
ally disease-free posttransplantation period may
econstitute both memory T cells biased toward
peciﬁc tumor recognition and better poised to
radicate residual disease and naive T cells that
revent late relapse through a new diversity of TAA
peciﬁcities.
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